EGFR and non-small cell lung carcinoma: Although patients in the ADAURA trial were not randomized to compare adjuvant osimertinib versus adjuvant chemotherapy +/˗ osimertinib, the preliminary results did not demonstrate that adjuvant chemotherapy was harmful in the context of resected EGFR-mutant NSCLC.